VEVYE (AFT Pharmaceuticals Pty Ltd)
Product name
VEVYE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
206 (255 working days)
Active ingredients
ciclosporin
Registration type
EOI
Indication
Vevye® is indicated in adult patients for the treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) which has not improved despite treatment with tear substitutes (see section 5.1 Pharmacodynamic Properties – Clinical Trials).